We understand that living with sarcoidosis can be challenging, and many of you are constantly seeking new treatment options. We want to share an important update regarding recently announced results from a pulmonary sarcoidosis clinical trial. Key Points: Trial...
The Foundation for Sarcoidosis Research (FSR) is proud to announce the recipients of the 2024 FSR Cardiac Sarcoidosis Grant, providing $200,000 in funding to advance groundbreaking research aimed at improving the diagnosis, management, and treatment of cardiac...
In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request for Opinion Letter on Clinical Trials and the Family and Medical Leave Act (FMLA) with the U.S. Department of Labor (DOL). On November 8, 2024, FSR received a letter of clarification...
On October 28, 2024, the Foundation for Sarcoidosis Research (FSR) hosted a groundbreaking Externally Led Patient-Focused Drug Development (EL-PFDD) meeting on sarcoidosis with the U.S. Food and Drug Administration (FDA). This virtual event attracted nearly 350...
